TAM
CLDX icon

Tocqueville Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Tocqueville Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-667
Closed -$2K – 772
2018
Q4 		$2K Hold
667
– – ﹤0.01% 739
2018
Q3 		$5K Hold
667
– – ﹤0.01% 811
2018
Q2 		$5K Hold
667
– – ﹤0.01% 820
2018
Q1 		$23K Hold
667
– – ﹤0.01% 819
2017
Q4 		$28K Hold
667
– – ﹤0.01% 790
2017
Q3 		$29K Hold
667
– – ﹤0.01% 801
2017
Q2 		$25K Hold
667
– – ﹤0.01% 780
2017
Q1 		$36K Hold
667
– – ﹤0.01% 791
2016
Q4 		$35K Hold
667
– – ﹤0.01% 794
2016
Q3 		$40K Hold
667
– – ﹤0.01% 814
2016
Q2 		$44K Hold
667
– – ﹤0.01% 826
2016
Q1 		$38K Sell
667
-4,226
-86% -$475K ﹤0.01% 847
2015
Q4 		$1.15M Buy
4,893
+1,733
+55% +$378K 0.02% 514
2015
Q3 		$500K Sell
3,160
-73
-2% -$20.7K 0.01% 696
2015
Q2 		$1.22M Buy
3,233
+66
+2% +$26.2K 0.01% 534
2015
Q1 		$1.32M Buy
3,167
+667
+27% +$239K 0.02% 540
2014
Q4 		$684K Buy
2,500
+580
+30% +$144K 0.01% 642
2014
Q3 		$373K Sell
1,920
-323
-14% -$70.4K ﹤0.01% 685
2014
Q2 		$549K Sell
2,243
-1,080
-33% -$244K 0.01% 702
2014
Q1 		$881K Buy
3,323
+200
+6% +$76.6K 0.01% 468
2013
Q4 		$1.13M Buy
3,123
+1,430
+84% +$551K 0.02% 432
2013
Q3 		$900K Buy
1,693
+320
+23% +$110K 0.01% 528
2013
Q2 		$322K Buy
+1,373
New +$270K ﹤0.01% 758

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tocqueville Asset Management's CLDX Position: Q1 2019 in Review

Tocqueville Asset Management sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 667 shares — an estimated $2K sold.

Tocqueville Asset Management first reported a position in CLDX in Q2 2013 and held it in 23 quarters. The position peaked at $1.32M in Q1 2015. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

  • Tocqueville Asset Management reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Tocqueville Asset Management sold 667 Celldex Therapeutics shares in Q1 2019, an estimated $2K.
  • Tocqueville Asset Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 23 quarters.
  • Tocqueville Asset Management's Celldex Therapeutics position peaked at $1.32M in Q1 2015.
  • 53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on Tocqueville Asset Management's 13F filing for Q1 2019, filed 30 Apr 2019.